Everything below concerns trans-3-hexenoyl. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
A free flow helmet supplies a continuous flow of air to the diver, and he breathes this as it flows past. Work of breathing is minimal, but flow rate must be high if the diver works hard, and this is noisy, affecting communications and requiring hearing protection to avoid damage to the ears. This type of helmet is popular where divers have to work hard in relatively shallow water for long periods. It is also useful when diving in contaminated environments, where the helmet is sealed onto a dry suit, and the entire system is kept at a slight positive pressure by adjusting the back-pressure of the exhaust valve, to ensure that there is no leakage into the helmet. This type of helmet is often large in volume, and as it is attached to the suit, it does not move with the head. The diver must move his body to face anything he wants to see. For this reason the faceplate is large and there is often an upper window or side windows to improve the field of vision.
Many new features for tandem mass analysis were gradually revealed by using the digital ion trap. Ions can be selectively removed from the ion trap by boundary ejection simply by varying the duty cycle of the digital waveform, instead of applying the conventional "resolving DC" voltage. Since rectangular waveforms are employed in the DIT, electrons can be injected into the trap during one of the voltage level without being accelerated up by the varying electric field. This enabled Electron-capture dissociation, which needs very low energy electron beam to interact with the trapped ions, achieved in the digital ion trap, without assistance of a magnetic field. Other forms of digital ion trap were also developed, including the linear ion trap constructed using printed circuit boards and the rods structure linear ion guide/trap. Two sets of switch circuitry were normally used to generate 2 phases of rectangular pulse waveform for two pairs of rods in case of the linear digital ion trap.
=== Sources === Philippe Jaussaud; Édouard-Raoul Brygoo (2004). Du Jardin au Muséum. Archives (in French). Paris: Muséum national d'histoire naturelle. p. 630. ISBN 978-2-85653-565-3. Annuaire et sites du Muséum national d'histoire naturelle, 40 p., MNHN, Paris, rééditions décennales. Ghislaine Prévos, Service documentation du Département des Galeries du Muséum national d'histoire naturelle, annuaire biographique du personnel.
Enzymatic specificity provides useful insight into enzyme structure, which ultimately determines and plays a role in physiological functions. Specificity studies also may provide information of the catalytic mechanism. Specificity is important for novel drug discovery and the field of clinical research, with new drugs being tested for its specificity to the target molecule in various rounds of clinical trials. Drugs must contain as specific as possible structures in order to minimize the possibility of off-target affects that would produce unfavorable symptoms in the patient. Drugs depend on the specificity of the designed molecules and formulations to inhibit particular molecular targets. Novel drug discovery progresses with experiments involving highly specific compounds. For example, the basis that drugs must successfully be proven to accomplish is both the ability to bind the target receptor in the physiological environment with high specificity and also its ability to transduce a signal to produce a favorable biological effect against the sickness or disease that the drug is intended to negate.
The barcoded DNA fragments are amplified using PCR to create a library of DNA fragments with identical barcodes. All the fragments derived from a given DNA molecule are tagged with the same barcode. This step increases the quantity of DNA for sequencing and reduces the chances of losing unique DNA fragments during sequencing. Droplets (or GEM) are later collected in a tube, and the emulsion is broken, releasing the amplified, barcoded DNA sequences. Standard Illumina next-generation sequencing technology can be used to sequence libraries. During sequencing, the barcodes are read along with the DNA sequences, allowing researchers and scientists to group together DNA fragments that originate from the same DNA molecule. Even though each DNA fragment is typically not fully sequenced, the information from many overlapping fragments in the same genomic region can be combined to reconstruct the long stretches of the genome. Therefore, a genome can be easily assembled from scratch without any prior reference.
Sources: en.wikipedia.org
Auto-oxidation reaction is also observed with common ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran, and 1,4-dioxane. An illustrative product is diethyl ether peroxide. Such compounds can result in a serious explosion when distilled. To minimize this problem, commercial samples of THF are often inhibited with butylated hydroxytoluene (BHT). Distillation of THF to dryness is avoided because the explosive peroxides concentrate in the residue. Although ether hydroperoxide often form adventitiously (i.e. autoxidation), they can be prepared in high yield by the acid-catalyzed addition of hydrogen peroxide to vinyl ethers: C2H5OCH=CH2 + H2O2 → C2H5OCH(OOH)CH3 Many industrial peroxides are produced using hydrogen peroxide. Reactions with aldehydes and ketones yield a series of compounds depending on conditions. Specific reactions include addition of hydrogen peroxide across the C=O double bond: R2C=O + H2O2 → R2C(OH)OOH In some cases, these hydroperoxides convert to give cyclic diperoxides:
== Other activities == Guillaume and his wife Donna were co-founders of Artists for a Free South Africa (later renamed Artists for a New South Africa) in 1989, along with a number of other Hollywood actors, including Alfre Woodard.
Hazard research is published: an analysis of GBD study data shows pre-50 early-onset cancer cases rose by ~80% in 30 years (5 Sep), a study shows decoupling rates in high-income countries are inadequate for Paris Agreement commitments and suggests post-growth approaches such as demand reduction strategies and reorienting the economy (5 Sep), evidence of impacts of chronic and extreme heat exposure during pregnancy accumulates (7 Sep), a study shows early prevention of type 2 diabetes may save many years of life (11 Sep), a study estimates around 5 million adults died from cardiovascular disease due to lead exposure in 2019 (11 Sep), shortly after a review about biodiversity-related harmful effects on ecosystems by non-native ant invasions (29 Jul), the fifth-costliest invasive species, the red fire ant, is reported to have established itself in the warming Europe via colonies in Sicily (11 Sep), a product testing study shows cleaning products emit substantial amounts of hazardous VOCs, such as chloroform, with the lowest quantities in green fragrance-free products (12 Sep), the planetary boundaries framework assessment gets updated, incorporating freshwater change as a sixth Earth system dimension above its capacity limit (13 Sep), news outlets report on a study (31 Aug) that shows daily aspartame consumption leads to heritable cognitive deficits in mice – and more broadly that the exposome of men may also affect the mental health of the next generation (19 Sep), a study reports an increasing global exposure to air pollution from fires (20 Sep).
==== Selachimorpha (True Sharks) ==== Superorder Galeomorphi Order Carcharhiniformes (Ground Sharks) Scyliorhinus torazame, Cloudy catshark (2018) Order Lamniformes (Mackerel Sharks) Carcharodon carcharias, Great white shark (2018) Order Orectolobiformes (Carpet Sharks) Chiloscyllium plagiosum, Whitespotted bamboo shark (2020) Chiloscyllium punctatum, Brownbanded bamboo shark (2018) Rhincodon typus, Whale shark (2017)
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.